olanzapine/fluoxetine / Generic mfg. - LARVOL DELTA

Evidence based interventions for bipolar disorder across phases and age groups: living umbrella review, evaluation, analysis, and communication hub (U-REACH) project. (PubMed, BMJ) - "The EBI-BD tool can help clinicians make evidence based, personalised treatment decisions for bipolar disorder. This resource can inform clinical guidelines and provides a foundation for continuously improving bipolar disorder care as new evidence emerges."

Journal • Review • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

A combination of fluoxetine and olanzapine for the treatment of an adolescent with severe misophonia. (PubMed, Dusunen Adam) - No abstract available

Journal

Neurophysiological resting-state EEG markers of catatonia in schizophrenia and mood disorders (OHBM 2026) - "For each feature extracted from the resting-state EEG, we performed a linear regression analysis on catatonia status with the following covariables: age, sex, treatment (total equivalent doses of diazepam, olanzapine, and fluoxetine, which were not correlated to each other, and associated diagnoses (i.e., neurodevelopmental and neurological disorders). The data warehouse was funded within the framework of France 2030 “Support for the creation of hospital health data warehouses”. This work has also been supported by the French government's "Investissements d'Avenir" PsyCARE (ANR-18-RHUS-0014) and by a French government grants managed by the Agence Nationale de la Recherche under the France 2030 program (ANR-22-EXPR0013) and EEG-MIND (ANR-22-EXPR0009)."

CNS Disorders • Epilepsy • Mood Disorders • Psychiatry • Schizophrenia

Neurophysiological markers of neurodevelopmental disorders in psychiatry (OHBM 2026) - "Several limitations must be considered: broad diagnostic categorization may obscure condition-specific patterns, and treatment effects (computed as olanzapine, fluoxetine, and diazepam equivalents) were not integrated into current analyses. Overall, normative modeling provides a powerful framework for identifying individual neurophysiological deviations in clinical populations, offering insights into neural mechanisms underlying psychiatric-neurodevelopmental comorbidities and enabling personalized assessments in clinical neuroscience. Acknowledgement ANR-18-RHUS-0014 (PsyCARE); ANR-22-EXPR0013 (PEPR-ProPsy); ANR-22-EXPR0009 (EEG-MIND)"

Neurodevelopmental • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Mental Retardation • Mood Disorders • Psychiatry

Efficacy and safety of pharmacological and non-invasive brain stimulation for adolescent bipolar depression: a systematic review and network meta-analysis. (PubMed, Int J Bipolar Disord) - "Due to the absence of shared comparators, pharmacological treatments and non-invasive brain stimulation (NIBS) were analyzed in separate evidence networks rather than being directly compared.Pharmacological treatments included lurasidone, olanzapine-fluoxetine combination (OFC), and quetiapine, while NIBS consisted of transcranial direct current stimulation (tDCS) and intermittent theta-burst stimulation (iTBS). These results suggest that lurasidone and tDCS may be promising options for symptom management in adolescents with BD, while quetiapine may be considered for preventing manic switching. Further studies, including head-to-head trials, are needed to better understand the long-term effects and address gaps in suicide risk management and multimodal treatment strategies."

Journal • Retrospective data • Review • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

Antipsychotics as Adjunct Therapy in Risk Reduction of Crisis Admission: An Analysis of Historical Patient Data (APA 2026) - "In this study we evaluated historic data of mood disorder patients on aripiprazole, brexpiprazole, cariprazine, quetiapine, and olanzapine-fluoxetine (Symbyax) to determine the rates and odds of crisis admission for those patients. Antipsychotics used as adjunct therapy have varied results with reductions in crisis admissions for patients with mood disorders. It was noted though that in patients on cariprazine, there is a reduced risk of crisis admission as compared to the population with the same diagnosis and not on antipsychotics. These results indicate that antipsychotics as adjunct therapy can be potentially useful in mitigating crisis admissions."

Clinical • Bipolar Disorder • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders

Psychosis in the context of Multiple Sclerosis: A Case Series (APA 2026) - "His psychiatric condition stabilized with risperidone and bupropion, and was cleared by psychiatry for discharge with outpatient follow-up...He was stabilized with olanzapine and fluoxetine, safety monitoring, and supportive psychotherapy...Early recognition, multidisciplinary management, and close neurology–psychiatry collaboration are essential to optimize outcomes. Further research is needed to clarify underlying mechanisms and guide treatment strategies."

Clinical • CNS Disorders • Cognitive Disorders • Depression • Major Depressive Disorder • Mood Disorders • Multiple Sclerosis • Psychiatry • Schizophrenia • Substance Abuse • Suicidal Ideation

Samidorphan Sadness: a Case of Depressive Symptoms Following Addition of Samidorphan (APA 2026) - "Description Background: Olanzapine (Zyprexa) is a second-generation antipsychotic approved for treatment of schizophrenia in adults and adolescents ages 13 years and older; acute manic or mixed episodes of bipolar 1 disorder as well as bipolar 1 disorder maintenance in patients 13 years and older; adjunct to lithium or valproic acid treatment in adult patients with bipolar 1 disorder (FDA, 2025); It is also available in several combined formulations, including as olanzapine-fluoxetine (Symbyax) for depression associated with bipolar 1 disorder in people 10 years and older, as well as treatment-resistant depression in adults (FDA, 2025), and olanzapine-samidorphan (Lybalvi) for management of schizophrenia, bipolar 1 disorder manic or mixed episodes as monotherapy or adjunct, as well as bipolar 1 maintenance monotherapy in adults (FDA, 2025)...The mu opioid receptor is an area of interest as a potential target to treat depression, and medications including samidorphan, a..."

Clinical • Bipolar Disorder • CNS Disorders • Depression • Metabolic Disorders • Mood Disorders • Schizophrenia

Neurophysiological Resting-State Markers of Catatonia in Schizophrenia and Mood Disorders. (PubMed, Schizophr Bull) - "Routine clinical EEG revealed quantitative neurophysiological differences between patients with and without catatonia in a transdiagnostic population with psychotic and mood disorders. PSD, alpha peak frequency, and microstate anomalies in catatonia shed light on its underlying pathophysiology, suggesting a probable neurodevelopmentally-related excitation/inhibition dysregulation. Importantly, this indicates that routine clinical EEG could be used for diagnostic biomarker development, which would ultimately improve early detection and treatment."

Biomarker • Journal • Retrospective data • CNS Disorders • Mood Disorders • Psychiatry • Schizophrenia

Treatment of bipolar depression: results from a comprehensive network meta-analysis and updated systematic review. (PubMed, Eur Neuropsychopharmacol) - "The original NMA showed that olanzapine plus fluoxetine, quetiapine, olanzapine, lurasidone, lumateperone, cariprazine, and lamotrigine were more efficacious than placebo in reducing depressive symptoms in BD with good confidence. The complementary systematic review identified 24 clinical trials, seven of which had published results suitable for meta-analysis; the remaining 17 studies were either ongoing or completed with no available results. Collectively, the NMA and systematic review findings can inform evidence-based care and the development of international treatment guidelines for bipolar depression."

Journal • Retrospective data • Review • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

Normalized vs factorized spectra: comparative spectrophotometric approaches for enhancing the resolution of zero-order absorption spectra of olanzapine and fluoxetine in mixtures. (PubMed, BMC Chem) - No abstract available

Journal

Bipolar major depression: A comprehensive review of pharmacotherapy. (PubMed, Nurse Pract) - "Effective options include quetiapine, lurasidone, and olanzapine-fluoxetine...Antidepressant monotherapy is discouraged. A patient-centered approach optimizing efficacy, safety, and stability is essential."

Journal • Review • Bipolar Disorder • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

National Pregnancy Registry for Psychiatric Medications (clinicaltrials.gov) - P=N/A | N=5000 | Recruiting | Sponsor: Massachusetts General Hospital

Trial completion date • Trial primary completion date • Psychiatry

Bipolar disorder in children, adolescents and young adults. Part 2. Therapeutic management. Recommendations under the patronage of the Executive Board of the Polish Psychiatric Association, National Consultants in the field of Psychiatry and National Consultants in Child and Adolescent Psychiatry. (PubMed, Psychiatr Pol) - "Lithium, aripiprazole, quetiapine, risperidone, olanzapine, asenapine, ziprasidone are recommended for the treatment of mania and mixed states. For the treatment of depressive episodes in bipolar disorder in children and adolescents, experts recommend lurasidone as monotherapy or olanzapine + fluoxetine as combination therapy. Although long-term treatment is a key aspect of bipolar disorder management in children and adolescents, consistent efficacy data are still lacking. Safety data indicate that the most commonly reported adverse reactions in children and adolescents treated with mood stabilizers are gastrointestinal and neurological adverse reactions, while the use of antipsychotics is mainly associated with weight gain and sedation."

Clinical guideline • Journal • Review • Anesthesia • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

CASE PRESENTER 2: LIMITED-RESOURCE SETTINGS AND A COMPLEX PSYCHIATRIC CASE: PSYCHOTIC BIPOLAR DEPRESSION WITH CATATONIA (WPA-WCP 2025) - "These included lamotrigine, quetiapine, alprazolam, biperiden, lorazepam (up to 12mg/day), fluoxetine, olanzapine, amantadine, aripiprazole, and clozapine. This case highlights the complexity of managing catatonia when significant psychotic symptoms are present, weighing the benefits and risks of psychoactive drugs. Additionally, a late brain magnetic resonance image showed an arachnoid cyst and microangiopathy, findings that could or not be involved in the patient's clinical presentation."

Clinical • Bipolar Disorder • CNS Disorders • Depression • Insomnia • Mood Disorders • Psychiatry • Sleep Disorder

Fixed dose combination dextromethorphan-bupropion: A hope for treatment resistant depression (TRD). (PubMed, Indian J Psychiatry) - "Olanzapine-fluoxetine combination, rTMS, Intravenous ketamine and Electroconvulsive therapy have been till now studied in TRD. Dextromethorphan-bupropion is a newer antidepressant, which has been found to be effective, fast-acting, and well tolerated medicine for depression. We used this novel antidepressant in three cases of TRD, alone and with combination, and it showed satisfactory response within 2 weeks."

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

Atypical Antipsychotics in Mood and Other Disorders: Are We Too Quick on the Draw? - A Panel Discussion (APA 2025) - "Following the 1989 advent of SGAs when clozapine was launched, these medications began their triumphant march across the pages of the DSM: prescribed on-label for Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression augmentation, irritability associated with Autism Spectrum Disorder, suicidal risk reduction; off-label for PTSD, sleep disorders, ADHD, Tourettes Disorder, OCD, panic disorder, eating disorders, and both on label and off label - depending on which SGA - agitation associated with Alzheimer's.`...In the 1960s and 70s there were several formulations which combined first generation antipsychotics with antidepressants in a single pill (e.g., amitriptyline+perphenazine, tranylcypromine+trifluoperazine.) Although these combinations are still available, they seemed to fall out of favor in the 1980s, perhaps as a result of increasing attention to the challenge of tardive dyskinesia and the increasing faith in newer antidepressants. (We..."

ADHD (Impulsive Aggression) • Alzheimer's Disease • Attention Deficit Hyperactivity Disorder • Autism Spectrum Disorder • Bipolar Disorder • CNS Disorders • Depression • Genetic Disorders • Major Depressive Disorder • Mood Disorders • Movement Disorders • Post-traumatic Stress Disorder • Psychiatry • Schizophrenia • Sleep Disorder • Tourette Syndrome

Electroconvulsive Therapy and the Onset of Diabetes: A Rare but Critical Complication in Children (ESPE-ESE 2025) - "Case Presentation A 13-year-old boy with early-onset psychosis and treatment-resistant ADHD had been on medication, including fluoxetine, olanzapine, quetiapine, and mianserin for the past two months. Conclusion Considering the uncertainty surrounding the etiology of childhood psychiatric disorders and the potential impact of ECT on glycemic control,the effect of ECT on beta cell reserve in children should be further evaluated. A multidisciplinary approach is essential during the ECT treatment process in children, with careful attention to hyperglycemic complications and more frequent monitoring of blood glucose levels."

Clinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Diabetes • Infectious Disease • Measles • Mental Retardation • Metabolic Disorders • Ocular Inflammation • Ophthalmology • Pediatrics • Psychiatry

An Overview of Psychiatric Disorders and Treatment in Patients with Lennox-Gastaut Syndrome in a LATAM Specialized Center (AAN 2025) - "Psychotropic medications were administered to 24 patients (60%), with 5 (12.5%) receiving risperidone as monotherapy, followed by sertraline in 3 (7.5%), fluoxetine in 2 (5%), and clonazepam, haloperidol, and quetiapine in 1 (2.5%) each. Additionally, polytherapy was utilized, including risperidone with SSRIs in 3 (7.5%) and fluoxetine with olanzapine in 2 (5%).The most common comorbidity was intellectual developmental impairments. The most common comorbidity was intellectual developmental impairments. Moreover, half of the patients had psychiatric comorbidities, with behavioral disturbances and psychosis being the most common, as documented in literature. This highlights the importance of early diagnosis and treatment, as these conditions worsen prognosis."

Clinical • CNS Disorders • Depression • Epilepsy • Mental Retardation • Psychiatry • Sleep Disorder

Ecofriendly and smart spectrophotometric approaches for synchronized analysis of two antipsychotic drugs, fluoxetine and olanzapine: application to combined tablet dosages with assessment of method greenness. (PubMed, BMC Chem) - "In conclusion, for FLX determination, the use of dual wavelength method is preferable because it needs very low mathematical treatment than the ratio subtraction method. However, for OLZ, the ratio subtraction method has higher sensitivity than absorptivity factor method although the latter is simpler."

Journal • CNS Disorders

Quantitative Evaluation of Multiple Treatment Regimens for Treatment-Resistant Depression. (PubMed, Int J Neuropsychopharmacol) - "The quantitative evaluation of 22 TRD treatments illuminates key pharmacodynamic parameters, bolstering the development of clinical guidelines and aiding the design of clinical trials and medical decision-making."

Journal • CNS Disorders • Depression • Mood Disorders • Pain • Psychiatry

The efficacy of valproate in acute mania, bipolar depression and maintenance therapy for bipolar disorder: an overview of systematic reviews with meta-analyses. (PubMed, BMJ Open) - "This overview highlights favourable results for valproate compared with placebo in all phases of BD, as well as presenting specific results in comparison with other active drugs. However, these results must be interpreted considering the methodological limitations of our study."

Clinical • Journal • Review • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

Youth With Bipolar Disorder: Pharmacologic Interventions and Strategies to Mitigate Adverse Effects (AACAP 2024) - "Lurasidone and olanzapine-fluoxetine combination are the only evidence-based US FDA-approved treatments for depression associated with bipolar disorder in youth... SGAs and lithium are evidence-based treatments for youth with bipolar disorder. Metabolic burden varies among SGAs and should inform treatment selection. Education regarding side effects, as well as healthy lifestyle intervention and metformin, should be considered as part of all antipsychotic treatment regimens."

Adverse events • Bipolar Disorder • CNS Disorders • Depression • Metabolic Disorders • Mood Disorders • Psychiatry

Spectrophotometric determination of olanzapine, fluoxetine HCL and its impurity using univariate and chemometrics methods reinforced by latin hypercube sampling: Validation and eco-friendliness assessments. (PubMed, BMC Chem) - "Statistical analysis revealed no noteworthy differences (P > 0.05) among the proposed and published techniques. Both pure powders and pharmaceutical capsules were analyzed via these methods."

Journal

LEGIONELLA TRIAD: A RARE PRESENTATION OF LEGIONNAIRES' DISEASE (CHEST 2024) - "He had been residing in a shelter and had a history of anxiety and depression, for which he was prescribed fluoxetine and olanzapine...The patient received aggressive hydration and levofloxacin at a dosage appropriate for patients with renal impairment... This case report highlights a distinct presentation of legionnaires disease associated rhabdomyolysis and acute renal failure and the need to maintain a high degree of suspicion for legionella pneumonia even in patients without classic symptoms like fever, especially for high-risk individuals like those residing in shelters. Our patient was successfully treated with aggressive hydration and appropriate antibiotics and didn't require initiation of hemodialysis, emphasizing the need for early recognition and prompt initiation of treatment."

Acute Kidney Injury • CNS Disorders • Cough • Depression • Hepatitis B • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Influenza • Musculoskeletal Pain • Nephrology • Novel Coronavirus Disease • Pain • Pneumococcal Infections • Pneumonia • Psychiatry • Renal Disease • Respiratory Diseases